Corresponding author:

2 Objectives. Wegener’s granulomatosis (WG) is a systemic vasculitis characterized by relapsing and remitting disease activity. Immunosuppressive drugs are used to control disease, but increase susceptibility to infection. Therefore, influenza vaccination should be considered in WG patients. This study was performed to assess immunogenicity of influenza vaccination in WG patients. Methods. We performed a randomized, controlled trial in WG patients with quiescent disease, defined as Birmingham Vasculitis Activity Score (BVAS) < 2. Patients were randomized to receive influenza vaccination (n = 49) or to participate as control (n = 23). In addition, healthy controls (n = 49) were vaccinated. At entry and at one and three to four months after entry, antibody responses to vaccination were determined. Furthermore, disease activity was measured (BVAS), adverse effects were recorded, and antineutrophil cytoplasmic autoantibodies (ANCA) titers were determined. Results. WG patients achieved high seroprotection rates to all three influenza strains